[go: up one dir, main page]

LU91314I2 - "Combinaison de particules viroides de papillomavirus humain de type 6, 11, 16 et 18 (GARDASIL -GilGARD )" - Google Patents

"Combinaison de particules viroides de papillomavirus humain de type 6, 11, 16 et 18 (GARDASIL -GilGARD )"

Info

Publication number
LU91314I2
LU91314I2 LU91314C LU91314C LU91314I2 LU 91314 I2 LU91314 I2 LU 91314I2 LU 91314 C LU91314 C LU 91314C LU 91314 C LU91314 C LU 91314C LU 91314 I2 LU91314 I2 LU 91314I2
Authority
LU
Luxembourg
Prior art keywords
gilgard
gardasil
combination
human papillomavirus
particles type
Prior art date
Application number
LU91314C
Other languages
English (en)
Other versions
LU91314I9 (fr
Original Assignee
Medimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Inc filed Critical Medimmune Inc
Publication of LU91314I2 publication Critical patent/LU91314I2/fr
Publication of LU91314I9 publication Critical patent/LU91314I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y10S977/804—Containing nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
LU91314C 1997-09-05 2007-02-21 "Combinaison de particules viroides de papillomavirus humain de type 6, 11, 16 et 18 (GARDASIL -GilGARD )" LU91314I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92399797A 1997-09-05 1997-09-05
PCT/US1998/016464 WO1999013056A1 (fr) 1997-09-05 1998-08-19 Methode de desassemblage-reassemblage in vitro de particules viroides (vlp) du papillomavirus

Publications (2)

Publication Number Publication Date
LU91314I2 true LU91314I2 (fr) 2007-04-23
LU91314I9 LU91314I9 (fr) 2019-01-30

Family

ID=25449564

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91314C LU91314I2 (fr) 1997-09-05 2007-02-21 "Combinaison de particules viroides de papillomavirus humain de type 6, 11, 16 et 18 (GARDASIL -GilGARD )"

Country Status (15)

Country Link
US (2) US6261765B1 (fr)
EP (2) EP1700911B1 (fr)
JP (2) JP4199416B2 (fr)
AT (1) ATE333501T1 (fr)
AU (1) AU742409B2 (fr)
CA (1) CA2302545C (fr)
CY (2) CY1107987T1 (fr)
DE (3) DE122007000015I1 (fr)
DK (1) DK1015561T3 (fr)
ES (2) ES2268787T3 (fr)
FR (1) FR07C0012I2 (fr)
LU (1) LU91314I2 (fr)
NL (1) NL300264I2 (fr)
PT (1) PT1015561E (fr)
WO (1) WO1999013056A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
DE69734829D1 (de) * 1996-07-17 2006-01-12 Us Health Infektiöse pseudovirale papillomavirus partikel
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US7351533B2 (en) * 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
DE60041889D1 (de) 1999-12-09 2009-05-07 Medimmune Inc In-vitro-methode zur zerlegung und zum wiederzusammenfügen von papillomavirusartigen partikeln
AU2001275438A1 (en) * 2000-07-06 2002-01-21 Georgetown University Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
CA2422635C (fr) * 2000-09-18 2011-11-15 Medimmune, Inc. Dosage in vitro destine a mesurer l'antigenicite d'un vaccin
CN1114690C (zh) * 2001-05-15 2003-07-16 乔良 乳头瘤假病毒及其制备方法
AU2003219760A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE10224111A1 (de) * 2002-05-29 2003-12-18 November Ag Molekulare Medizin Verfahren zum Assemblieren von Untereinheiten zu Kapsoiden
EP1545625B1 (fr) * 2002-06-07 2011-08-24 Kentucky Bioprocessing, LLC Plateforme flexible d' assemblage et d' administration de vaccins
DE60336581D1 (de) 2002-12-20 2011-05-12 Glaxosmithkline Biolog Sa Verwendung von HPV16 und HPV18 VLPs als Vakzine gegen eine oder mehrere onkogene HPV des Typus 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
CA2572129A1 (fr) 2004-07-01 2006-01-12 The Circle For The Promotion Of Science And Engineering Construction ressemblant a une particule virale et procede servant a former celle-ci dans des conditions physiologiques
CA2608515A1 (fr) * 2005-06-01 2007-05-10 Dow Global Technolgies Inc. Production de particules multivalentes semblables a des virus
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
AU2008224877B2 (en) 2007-03-14 2013-07-11 Ligocyte Pharmaceuticals, Inc. Virus like particle purification
EP2139993A2 (fr) * 2007-04-27 2010-01-06 Dow Global Technologies Inc. Production améliorée et assemblage in vivo de particules icosaédriques solubles recombinées analogues à un virus
WO2008140961A2 (fr) * 2007-05-08 2008-11-20 The Government Of The U.S.A, As Represented By The Secretary, Department Of Health And Human Services Pseudovirus de papillomavirus pour détection et thérapie de tumeurs
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
US8663951B2 (en) * 2009-01-09 2014-03-04 Academia Sinica Method of producing virus-like particles of picornavirus using a small-ubiquitin-related fusion protein expression system
EP3427755B1 (fr) 2009-04-13 2020-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Particules hpv et utilisations associées
BRPI1014718A2 (pt) 2009-06-25 2016-04-12 Glaxonsmithkline Biolog S A polipeptídeo do papiloma vírus humano, capsômero, partícula tipo vírus, composição imunogência, molécula de ácido nucléico, e, métodos para produzir o polipeptídeo, e, para preparar uma composição imunogênica
WO2011000058A1 (fr) * 2009-07-03 2011-01-06 The University Of Queensland Procédé de préparation d'une structure biologique particulaire
WO2011039646A2 (fr) 2009-09-30 2011-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Ciblage de particules d'administration de gène de papillomavirus
US20130115247A1 (en) * 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
US20130116408A1 (en) * 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
WO2013119877A1 (fr) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Nanosphères dérivées de virions pour l'administration sélective d'agents thérapeutiques et diagnostiques dans des cellules cancéreuses
JP2015514696A (ja) 2012-03-18 2015-05-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ヒト・パピローマウイルスに対するワクチン接種方法
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
KR101559622B1 (ko) 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
US10117947B2 (en) 2013-09-18 2018-11-06 Aura Biosciences, Inc. Virus-like particle conjugates for diagnosis and treatment of tumors
JP2017528137A (ja) * 2014-09-11 2017-09-28 カディラ ヘルスケア リミティド 卓越した免疫学的特性を有する卓越したヒトパピローマウイルス抗原及びそれを含むワクチン
EA201790944A1 (ru) * 2014-12-26 2017-11-30 Айджин, Инк. Способ получения вирусоподобных частиц папилломавируса человека
JP7115982B2 (ja) 2015-10-30 2022-08-09 アレタ・バイオセラピューティクス・インコーポレイテッド 癌の治療のための組成物及び方法
BR112018008783A8 (pt) 2015-10-30 2019-02-26 Aleta Biotherapeutics Inc terapia-alvo de câncer
MA43134A (fr) 2015-10-30 2018-09-05 Aleta Biotherapeutics Inc Compositions et méthodes de transduction tumorale
GB201708709D0 (en) * 2017-06-01 2017-07-19 Univ York Virus like particle
KR20250044945A (ko) 2017-11-06 2025-04-01 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 기존의 미생물 면역을 활용한 암 치료
EP3710468A1 (fr) 2017-11-14 2020-09-23 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Papillomavirus non humains pour administration de gènes in vitro et in vivo
CA3182021A1 (fr) * 2020-06-09 2021-12-16 Scot R. Shepard Procede d'assemblage de particules de type viral a deux constituants
GB202011609D0 (en) 2020-07-27 2020-09-09 Univ Leeds Innovations Ltd Coronaviral packaging signals
JP2026000483A (ja) * 2022-11-22 2026-01-06 一般財団法人阪大微生物病研究会 安定化されたｖｌｐワクチン

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016638A1 (fr) * 1991-03-14 1992-10-01 5 Prime --> 3 Prime, Inc. Vehicules de transduction pour le transfert de l'adn a une cellule de mammifere
FR2768749A1 (fr) * 1997-09-22 1999-03-26 Inst Nat Sante Rech Med Virus artificiels derives de papillomavirus, et leurs utilisations, notamment en therapie genique

Also Published As

Publication number Publication date
AU742409B2 (en) 2002-01-03
CA2302545C (fr) 2012-04-03
LU91314I9 (fr) 2019-01-30
ES2268787T3 (es) 2007-03-16
ATE333501T1 (de) 2006-08-15
FR07C0012I1 (fr) 2007-03-30
JP2009057377A (ja) 2009-03-19
AU9015498A (en) 1999-03-29
DE122007000015I2 (de) 2008-01-24
CA2302545A1 (fr) 1999-03-18
CY1107987T1 (el) 2011-04-06
EP1015561A1 (fr) 2000-07-05
PT1015561E (pt) 2006-11-30
ES2572628T3 (es) 2016-06-01
CY2007007I1 (el) 2009-11-04
FR07C0012I2 (fr) 2007-10-26
DK1015561T3 (da) 2006-11-13
DE69835294T2 (de) 2007-07-26
CY2007007I2 (el) 2016-10-05
DE69835294D1 (de) 2006-08-31
HK1030797A1 (en) 2001-05-18
US6261765B1 (en) 2001-07-17
JP4199416B2 (ja) 2008-12-17
EP1015561B1 (fr) 2006-07-19
DE122007000015I1 (de) 2007-05-24
US6416945B1 (en) 2002-07-09
NL300264I2 (nl) 2008-06-02
NL300264I1 (nl) 2007-05-01
EP1700911B1 (fr) 2016-04-06
WO1999013056A1 (fr) 1999-03-18
JP2001515922A (ja) 2001-09-25
JP4486142B2 (ja) 2010-06-23
EP1700911A1 (fr) 2006-09-13

Similar Documents

Publication Publication Date Title
LU91314I2 (fr) "Combinaison de particules viroides de papillomavirus humain de type 6, 11, 16 et 18 (GARDASIL -GilGARD )"
DE69535018D1 (de) Papillomavirus vakzine
TR200001842T2 (tr) Papilloma virüs kapsomer aşı formülasyonları- kullanım metotları.
MY132529A (en) Paroxetine hydrochloride anhydrate
ATE322252T1 (de) Verfahren zur herstellung und sammlung von kristallinen partikeln
DE69521521D1 (de) Mono- oder polyfunktionelle konjugate von polylysine
AU6093296A (en) Infectious dengue 2 virus pdk-53 as quadravalent vaccine
WO1996029413A3 (fr) Adn codant le virus du papillome de type 18 humain
EA199700281A1 (ru) Молекула днк, кодирующая белок l1 вируса папилломы типа 11 чепловека, экспрессирующий вектор, способ получения очищенных вирусоподобных частиц
IL148371A0 (en) Process to separate 1,3-propanediol or glycerol, or a mixture thereof from a biological mixture
EA200701633A1 (ru) Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
WO1997005899A3 (fr) Nouveaux vaccins et nouvelles compositions pharmaceutiques utilisant des vesicules de membrane de micro-organismes et leurs procedes d'elaboration
CA2200582A1 (fr) Adn codant pour le papillomavirus humain du type 6a
EA199800102A1 (ru) Получение производных бициклогексана
AU8580298A (en) Artificial system for the production of infectious human papillomavirus
DK0750669T3 (da) Modificeret papillomavirus-L2-protein og VLP'er dannet derudfra
KR950700988A (ko) 미생물, 이들의 제조방법 및 이들의 사용(Micro-organisms, preparation method therefor and uses thereof)
BR0204057A (pt) Processos para geração de terahertz
DK0796256T3 (da) Fremgangsmåde til fremstilling af ranitidin
AU4457397A (en) Model for the papilloma virus infection (in vivo), consisting of the scid-bo mouse
FR2580176B1 (fr) Vaccin antirabique avirulent
TR200402685T4 (tr) Merkezi sinir sistemi üzerine etki eden siklobüta-indol karboksamid türevleri, bunların hazırlanma yöntemleri ve bunları içeren farmasötik bileşimler.
IT8919982A0 (it) Metodo per regolare la quantita' d'aria fornita ad una maschera antigas, e maschera antigas utilizzante il metodo.
RU94020673A (ru) Средство против вирусов герпеса
IT236778Y1 (it) Tavolo atto a ridurre l'inquinamento dell'aria derivante da fumoo da altre sostanze particolarmente per locali pubblici